Simultaneous Application of Ketamine and Lidocaine During an Ambulatory Infusion Therapy as a Treatment Option in Refractory Chronic Pain Conditions

University Hospital, Basel, Switzerland319 enrolled

Overview

This study is to retrospective investigate the effects of the simultaneous intravenous (i.v.) administration of lidocaine and ketamine on a four to six weeks interval in treatment refractory different chronic pain conditions.

The use of intravenous infusion therapy with lidocaine or ketamine has been of interest in several chronic pain conditions. Studies showed a benefit in immediate pain reduction and even longer lasting pain relief for treatment approaches with lidocaine and ketamine. While there is a broad database on the use of lidocaine and ketamine in chronic pain management as separate agents, very few pre-clinical animal studies have investigated the combined use of said analgesics and none of them reports their combined use in chronic pain patients. This study is to retrospective investigate the effects of the simultaneous i.v. administration of lidocaine and ketamine on a four to six weeks interval in treatment refractory different chronic pain conditions.

Study Type

OBSERVATIONAL

Enrollment

319

Conditions

Chronic Pain

Interventions

Data collection for statistical analysis to identify patterns of treatment response/ non-responseOTHER

All data are restricted from the patient physical and electronic record of the Pain Management-Unit of the University Hospital Basel. No external data sources will be used. Records will be screened from 2012- May 2021. Variables collected are e.g. demography, medical diagnosis, psychological diagnosis, infusion therapy, medication, pain.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * ICD11 Medical diagnosis of chronic pain and its subcategories * Treatment with intravenous lidocaine and ketamine infusions during the years of 2012 to May 2021 at our pain unit at the USB * Patient is at least 18 years of age at the beginning of the first infusion treatment Exclusion Criteria: * Patient is underage at the beginning of the first infusion treatment * Documented written refusal of consent for research (general consent or specific study consent) * Patients undergoing treatment with only lidocaine or ketamine respective

Locations (1)

Department of Anesthesiology, University of Basel (USB)

Basel, Switzerland

Outcomes

Primary Outcomes

Pain reduction over time (long lasting)

The primary outcome (pain reduction over time) is explorative and not comparative, therefore no hypothesis is formulated and only descriptive/explorative statistics will be applied. Pain reduction will be analysed descriptively. Categories: any pain reduction/ pain reduction \>=50%/ pain free/ increase in pain (recorded as "no time stated/ \< 2 weeks/ ≥2 weeks/full time in-between infusions"

Time frame: up to 1 year

Secondary Outcomes

Change in Pain (acute reduction)

Numeric rating scale (NRS) at start of infusion (recorded as number from 0 = no pain to 10 = maximal pain)/ NRS at end of infusion (recorded as number from 0 to 10)

Time frame: up to 1 day

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.